At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,590 enrolled
Drug / intervention
Rimegepant +1 moredrug
Likely dose
Rimegepant 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention
In Brief
A Phase 3 clinical trial evaluating Rimegepant and Placebo for Migraine. Completed, enrolled 1,590 participants across 93 sites.
Detailed Summary
The purpose of this is study is to compare the efficacy of BHV-3000 (rimegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartNov 2018
Primary CompletionDec 2019
Study CompletionFeb 2021
TodayJul 2026
First PostedNov 6, 2018
Enrollment StartNov 14, 2018
Primary CompletionDec 10, 2019
Study CompletionFeb 2, 2021
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.7 years ago
Interventions
Rimegepantdrug
Rimegepant 75 mg tablet EOD
Placebodrug
Placebo tablet to match rimegepant tablet EOD